JP2013518061A5 - - Google Patents

Download PDF

Info

Publication number
JP2013518061A5
JP2013518061A5 JP2012550265A JP2012550265A JP2013518061A5 JP 2013518061 A5 JP2013518061 A5 JP 2013518061A5 JP 2012550265 A JP2012550265 A JP 2012550265A JP 2012550265 A JP2012550265 A JP 2012550265A JP 2013518061 A5 JP2013518061 A5 JP 2013518061A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
phenylaminoethane
hydrazide
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012550265A
Other languages
English (en)
Japanese (ja)
Other versions
JP5788907B2 (ja
JP2013518061A (ja
Filing date
Publication date
Priority claimed from AT0012210A external-priority patent/AT509045B1/de
Application filed filed Critical
Publication of JP2013518061A publication Critical patent/JP2013518061A/ja
Publication of JP2013518061A5 publication Critical patent/JP2013518061A5/ja
Application granted granted Critical
Publication of JP5788907B2 publication Critical patent/JP5788907B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012550265A 2010-01-29 2011-01-28 疾患の治療に使用される化合物 Expired - Fee Related JP5788907B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0012210A AT509045B1 (de) 2010-01-29 2010-01-29 Verbindungen zur behandlung von asthma bronchiale
ATA122/2010 2010-01-29
PCT/AT2011/000050 WO2011091461A1 (de) 2010-01-29 2011-01-28 Verbindungen zur verwendung bei der behandlung von erkrankungen

Publications (3)

Publication Number Publication Date
JP2013518061A JP2013518061A (ja) 2013-05-20
JP2013518061A5 true JP2013518061A5 (enExample) 2014-02-13
JP5788907B2 JP5788907B2 (ja) 2015-10-07

Family

ID=43707937

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012550265A Expired - Fee Related JP5788907B2 (ja) 2010-01-29 2011-01-28 疾患の治療に使用される化合物

Country Status (12)

Country Link
US (1) US20130065962A1 (enExample)
EP (2) EP2965755A1 (enExample)
JP (1) JP5788907B2 (enExample)
KR (1) KR20120128644A (enExample)
CN (2) CN104958286B (enExample)
AT (1) AT509045B1 (enExample)
AU (1) AU2011208939B2 (enExample)
BR (1) BR112012018772A2 (enExample)
CA (1) CA2788326A1 (enExample)
MX (1) MX2012008815A (enExample)
SG (1) SG182786A1 (enExample)
WO (1) WO2011091461A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013302177A1 (en) * 2012-08-10 2015-03-26 Mcmaster University Antibacterial inhibitors
TWI689490B (zh) * 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
SG11201702812PA (en) * 2014-10-10 2017-05-30 Prometic Pharma Smt Ltd Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes
EP3323428A1 (en) * 2016-11-17 2018-05-23 CNRS Centre National de la Recherche Scientifique Selective c-flip inhibitors as anticancer agents

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082846A (en) 1976-11-18 1978-04-04 University Of Utah Method for treating psoriasis
JPH02753A (ja) * 1987-12-24 1990-01-05 Ono Pharmaceut Co Ltd カルバゾイル誘導体、それらの製造方法およびそれらを有効成分として含有するメイラード反応阻害剤
EP0323590A3 (en) 1987-12-24 1990-05-02 Ono Pharmaceutical Co., Ltd. Carbazoyl derivatives
WO1992017065A2 (en) 1991-04-01 1992-10-15 Duke University Method of inhibiting fibrosis
US5324747A (en) * 1992-07-15 1994-06-28 Hoffmann-La Roche Inc. N-substituted anilines, inhibitors of phospholipases A2
CH683965A5 (it) * 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
US6197743B1 (en) * 1996-07-26 2001-03-06 The Trustees Of Boston University Compositions and methods for the treatment of viral disorders
US5741926A (en) * 1997-02-12 1998-04-21 Shaman Pharmaceuticals, Inc. Aniline derivatives having antihyperglycemic activity
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
CA2324426A1 (en) * 1998-02-11 1999-08-19 Douglas V. Faller Compositions and methods for the treatment of cystic fibrosis
WO2000015215A1 (en) * 1998-09-15 2000-03-23 Korea Research Institute Of Bioscience And Biotechnology Composition containing cinnamic acid derivatives for preventing or treating elevated blood lipid level-related diseases
AU2004242565A1 (en) * 1999-01-12 2005-01-27 Kenneth Blum Treatment of hypertension with compounds that inhibit the destruction of enkephalins or endorphins
US6610715B1 (en) 1999-05-28 2003-08-26 Cheil Jedang Corporation Cathecol hydrazone derivatives, process for preparing the same and pharmaceutical composition containing the same
IT1313567B1 (it) * 1999-07-27 2002-09-09 Zambon Spa Uso della n-acetil-cisteina per la preparazione di composizionifarmaceutiche topiche per il trattamento di patologie allergiche delle
US6444829B1 (en) 2000-07-19 2002-09-03 Hoffmann-La Roche Inc. Pyrrolidine compounds
WO2003084940A1 (en) 2002-04-08 2003-10-16 Alangudi Sankaranarayanan Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
US7741352B2 (en) 2003-03-11 2010-06-22 Neurosearch A/S KCNQ channel modulating compounds and their pharmaceutical use
WO2005085185A1 (en) 2004-03-03 2005-09-15 Smithkline Beecham Corporation Aniline derivatives as selective androgen receptor modulators
DE102004028862A1 (de) 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
CN1686297A (zh) * 2005-04-07 2005-10-26 甘肃圣达医药科技有限责任公司 一种止咳平喘药物及其制备方法
CU23431B6 (es) * 2005-05-12 2009-10-16 Ct Ingenieria Genetica Biotech Método para la inhibición de la proliferación de células tumorales y el tratamiento del cáncer
WO2007026215A1 (en) 2005-08-29 2007-03-08 Glenmark Pharmaceuticals S.A. Pyrazole derivatives as cannabinoid receptor ligands, pharmaceutical compositions containing? them, and processes for their preparation
DE102006005179A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Aminoindazolderivate
PT2061765E (pt) * 2006-09-01 2015-02-06 Senhwa Biosciences Inc Moduladores de serina-treonina-proteína-quinase e de parp
BRPI0809974A2 (pt) 2007-03-30 2014-10-07 Sanofi Aventis Compostos de pirimidina hidrazida como inibidores de pgds
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為vap-1抑制劑之用途
TWI485134B (zh) * 2009-05-04 2015-05-21 波麥堤克生化科學公司 取代的芳族化合物及其藥學用途

Similar Documents

Publication Publication Date Title
JP2023002662A5 (enExample)
JP2016534063A5 (enExample)
JP2009514874A5 (enExample)
JP2010518122A5 (enExample)
JP2010077141A5 (enExample)
JP2012502037A5 (enExample)
JP2013542247A5 (enExample)
JP2011201907A5 (enExample)
JP2016534153A5 (enExample)
JP2015057436A5 (enExample)
JP2014505107A5 (enExample)
JP2009102342A5 (enExample)
JP2012520866A5 (enExample)
JP2013507415A5 (enExample)
JP2013518107A5 (enExample)
JP2013520405A5 (enExample)
JP2018518537A5 (enExample)
JP2006182786A5 (enExample)
JP2014500861A5 (enExample)
JP2017526716A5 (enExample)
JP2013508279A5 (enExample)
JP2010521417A5 (enExample)
JP2014516942A5 (enExample)
US10016397B2 (en) Selective AT2 receptor agonists for use in treatment of cachexia
JP2017222722A5 (enExample)